A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
Trial details
- Registry ID
- NCT04401475
- Drugs studied
- SOC plus 15mg/kg EB05 IV
TrialRedline tracks 3 clinical trials sponsored by Edesa Biotech Inc.: 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19NCT04401475 | SOC plus 15mg/kg EB05 IV | Terminated | 2024-07-22Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental VitiligoNCT07889492 | EB06 | Recruiting | 2027-12Estimated |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact DermatitisNCT03680131 | EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0% | Completed | 2022-09-21Actual |
Names as written in the registry records.
NCT07889492 · Edesa Biotech Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of facial vitiligo that combines the extent of facial involvement and degree of depigmentation. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks. After: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of the extent and degree of depigmentation affecting the face with scores ranging from 0 to 3.5, where higher scores indicate greater facial vitiligo involvement. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mortality rate at Day 28 from IP administration. Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days. After: Measure: Mortality rate at Day 28 from IP administration. (Phase 2 and 3) Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days.
Before: Estimated. After: Actual.
Before: 644 participants (planned). After: 278 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2024. After: 22 Jul 2024.
Before: Suspended. After: Terminated.